Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 2, pp. 193-202
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine
Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2211-2222
Open Access | Times Cited: 23
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Hartmut Döhner, Courtney D. DiNardo, Frederick Appelbaum, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2169-2173
Closed Access | Times Cited: 20
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Omer Karrar, Maymona Abdelmagid, Masooma S Rana, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 2
Open Access | Times Cited: 16
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Shai Shimony, Jacqueline S. Garcia, Julia Keating, et al.
Leukemia (2024) Vol. 38, Iss. 7, pp. 1494-1500
Open Access | Times Cited: 6
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
Kari Hemminki, Frantisek Zitricky, Asta Försti, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
What have we learned about TP53-mutated acute myeloid leukemia?
Moazzam Shahzad, Muhammad Kashif Amin, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Rabia Shahswar, Razif Gabdoulline, K Krueger, et al.
Leukemia (2025)
Open Access
Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients
Linya Wang, Haitao Gao, Qiang Fu, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 586-586
Open Access
Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries
Kari Hemminki, Frantisek Zitricky
Annals of Hematology (2025)
Open Access
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Mithun Vinod Shah, Daniel A. Arber, Devendra Hiwase
American Journal of Hematology (2025)
Open Access
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Jayastu Senapati, Tapan M. Kadia, Naval Daver, et al.
Cancer (2025) Vol. 131, Iss. 7
Closed Access
Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy
A Schupbach, Dilara Akhoundova, Ulrike Bacher, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1138-1138
Open Access
Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax‐based therapy in the real world: Hokkaido Leukemia Net Study
Naoki Miyashita, Masahiro Onozawa, Toshihiro Matsukawa, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1549-1553
Closed Access | Times Cited: 3
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Deleted Journal (2024) Vol. 1, Iss. 3, pp. 100017-100017
Open Access | Times Cited: 3
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
Sylvain Garciaz, Pierre‐Yves Dumas, Sarah Bertoli, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 10, pp. 1870-1876
Open Access | Times Cited: 3
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, et al.
American Journal of Hematology (2024)
Open Access | Times Cited: 3
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1790-1801
Closed Access | Times Cited: 2
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
Francis LeBlanc, Erin H. Breese, Karen Burns, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 1055-1066
Open Access | Times Cited: 2
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification
Chao‐Ling Wan, Yuqing Liu, Fangtong Liu, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 723-739
Closed Access | Times Cited: 2
Issue Information

American Journal of Hematology (2024) Vol. 99, Iss. 2, pp. 147-149
Open Access | Times Cited: 1
The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
Shyam A. Patel
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1137-1138
Open Access | Times Cited: 1
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 515-518
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top